Navigation Links
IDIBELL researchers discover a substance against the 'dark genome' of cancer
Date:2/28/2011

A research study coordinated by Manel Esteller, researcher at Bellvitge Biomedical Research Institute (IDIBELL) has identified a substance that inhibits cancer growth by activating the so‑called "dark genome" (or non‑coding DNA) and micro‑RNA molecules. The study appears this week in the journal Proceedings of the National Academy of Sciences (PNAS).

Human body cells have a genome (the set of our DNA) encoding our proteins such as keratin in the skin or haemoglobin in blood. This genome with encoding DNA represents only the 5% of our genetic material. The remaining 95% is called the 'dark genome' or non-coding DNA and its role is largely unknown. Part of this DNA produces small charged molecules called micro-RNAs that activate or deactivate genes. In recent years it has been shown that alterations in these molecules are related to tumour onset.

Enoxacine

Researchers have shown that a small-molecule called enoxacin, used in antibacterial compounds, binds to the protein that builds micro-RNA and stimulates their inhibitory activity of the tumour growth. According to researcher Manel Esteller, that "is like if we have a second hand car and we put on a new engine".

The molecule has been tested both in laboratory cells and in animal models and now its behaviour should be studied in humans. Esteller stresses that the advantage of this compound is that we know its metabolism and its human security. Esteller adds that "although the use of this molecule may not be approved in cancer treatment, this finding opens the door to design new drugs that use microRNA as a therapeutic target. We show the pharmaceutical industry a new direction where to direct their efforts in anti-tumour therapy."


'/>"/>

Contact: Arantxa Mena
comunicacio@idibell.cat
34-932-607-129
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. Wayne State University researchers publish results settling multiple sclerosis debate
2. E-health must be a priority, researchers say
3. Mayo Clinic researchers confirm value of therapeutic hypothermia after cardiac arrest
4. Mayo researchers, Rochester educators, students to present at science conference
5. Researchers work at the frontiers of islet cell transplantation
6. Brain Appears to Be a Task Machine, Researchers Say
7. Researchers develop outline that may help weigh benefits of new imaging technologies
8. University of Minnesota researchers study the use of computer vision to diagnose mental disorders
9. Researchers find brain insulin plays critical role in the development of diabetes
10. Financial planning a key but neglected component of Alzheimers care, say researchers
11. Researchers find reduced levels of an important neurotransmitter in MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by ... and deal with these stressors is to adopt a more healthful diet, but too ... Risa Groux, a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... Fort Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... on Monday, May 16, 2016, at its new location in the Exchange Furniture Mall ... including a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... its digital health technology platform, which specializes in ... programs into scalable digital products, Zillion enables companies ... and empower consumers to take control of their ... live video conferencing – including one-to-one, group and ...
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
Breaking Medicine Technology: